<DOC>
	<DOC>NCT00189696</DOC>
	<brief_summary>This study will examine the efficacy, safety and tolerability of oral dose of YM060, 5-HT3 receptor antagonist, in patients with d-IBS.</brief_summary>
	<brief_title>Phase 3 Study of YM060 in Patients With Diarrhea-predominant Irritable Bowel Syndrome (d-IBS)</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<mesh_term>Ramosetron</mesh_term>
	<criteria>Patients satisfying the Rome II Diagnostic Criteria. Patients in whom no organic changes were observed in large intestine. Patients have diseases which interfere with evaluation of the efficacy and safety in this study. Patients are receiving and/or have received prior to the enrollment the treatment which interfere with evaluation of the efficacy and safety in this study.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Irritable Bowel Syndrome, Diarrhea</keyword>
</DOC>